Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis

Molecular Cancer Research

Volumn 10, Issue 5, 2012, Pages 597-604

  Pollari, Sirkku ^a   Käkönen, Rami S ^c   Mohammad, Khalid S ^e   Rissanen, Jukka P ^c   Halleen, Jussi M ^c   Wärri, Anni ^b   Nissinen, Liisa ^d   Pihlavisto, Marjo ^d   Marjamäki, Anne ^d   Perälä, Merja ^a   Guise, Theresa A ^e   Kallioniemi, Olli ^a,f   Käkönen, Sanna Maria ^b  

^a TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Pharmatest Services Ltd   (Finland)

^d Biotie Therapies Corp   (Finland)

^e INDIANA UNIVERSITY   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; DALTEPARIN; GLUCOSAMINE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; INTERLEUKIN 11; K5 DERIVED HEPARIN LIKE POLYSACCHARIDE; POLYSACCHARIDE; SMALL INTERFERING RNA; SULFOTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FEMALE; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; METASTASIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BACTERIAL CAPSULES; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARIN; HUMANS; INTERLEUKIN-11; MICE; MICE, NUDE; OSTEOCLASTS; RNA, SMALL INTERFERING; SULFOTRANSFERASES; TRANSFORMING GROWTH FACTOR BETA;

ESCHERICHIA COLI; MUS MUSCULUS;

EID: 84861160271     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0482     Document Type: Article

References (37)

1. Kozlow W, Guise TA. Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-80. (Pubitemid 41031006)
2. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011;71:175-84.
3. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? the influence of heparins on cancer spread. Thromb Haemost 1999;82: 947-52.
4. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-8. (Pubitemid 41095187)
5. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5. (Pubitemid 46218704)
6. Pollari S, Kakonen SM, Edgren H, Wolf M, Kohonen P, Sara H, et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 2011;125: 421-30.
7. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, et al. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res 1994;263:271-84. (Pubitemid 24320402)
8. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988;48:6876-81. (Pubitemid 19012221)
9. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9. (Pubitemid 26327863)
10. Rissanen JP, Ylipahkala H, Fagerlund KM, Long C, Vaananen HK, Halleen JM. Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab 2009;27:105-9.
11. Selander K, Lehenkari P, Vaananen HK. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994;55:368-75. (Pubitemid 24332745)
12. Delaisse JM, Eeckhout Y, Vaes G. Inhibition of bone resorption in culture by inhibitors of thiol proteinases. Biochem J 1980;192:365-8. (Pubitemid 11207938)
13. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:13909-14. (Pubitemid 41377677)
14. Gupta J, Robbins J, Jilling T, Seth P. TGFbeta-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther 2011;11:311-6.
15. Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem 1997;272:18000-6. (Pubitemid 27306378)
16. McCaffrey TA, Falcone DJ, Brayton CF, Agarwal LA, Welt FG, Weksler BB. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol 1989;109:441-8. (Pubitemid 19180150)
17. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol 1994;159:51-9. (Pubitemid 24234576)
18. Nakato H, Kimata K. Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim Biophys Acta 2002;1573:312-8. (Pubitemid 35335440)
19. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: An information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 1994;5:353-77. (Pubitemid 124004659)
20. Lyon M, Gallagher JT. Hepatocyte growth factor/scatter factor: a heparan sulphate-binding pleiotropic growth factor. Biochem Soc Trans 1994;22:365-70. (Pubitemid 24166188)
21. BorgenstromM, Warri A, Hiilesvuo K, Kakonen R, Kakonen S, Nissinen L, et al. O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost 2007;33:547-56. (Pubitemid 47105746)
22. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001;98:3352-7. (Pubitemid 32220849)
23. Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB, Frimundt Petersen C. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep 2005;14:99-104.
24. Poggi A, Rossi C, Casella N, Bruno C, Sturiale L, Dossi C, et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin Thromb Hemost 2002;28:383-92.
25. Szende B, Paku S, Racz G, Kopper L. Effect of fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Res 2005;25: 2869-72. (Pubitemid 41044674)
26. Yee CK, Butcher M, Zeadin M, Weitz JI, Shaughnessy SG. Inhibition of osteolytic bone metastasis by unfractionated heparin. Clin Exp Metastasis 2008;25:903-11.
27. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996;75:254-7.
28. Hawkins D, Evans J. Minimising the risk of heparin-induced osteoporosis during pregnancy. Expert Opin Drug Saf 2005;4:583-90. (Pubitemid 40723729)
29. Nelson-Piercy C. Heparin-induced osteoporosis. Scand J Rheumatol Suppl 1998;107:68-71. (Pubitemid 28432949)
30. Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998;80:413-7. (Pubitemid 28438735)
31. Kock HJ, Handschin AE. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: An in-vitro investigation. Clin Appl Thromb Hemost 2002;8:251-5.
32. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996;88:1314-20. (Pubitemid 26276806)
33. Nishiyama M, Itoh F, Ujiie A. Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol 1997;74:59-68. (Pubitemid 27254698)
34. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-73.
35. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008;122:293-8. (Pubitemid 351888881)
36. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux (arixtra) on human osteoblasts in vitro. Br J Surg 2005;92:177-83. (Pubitemid 40269331)
37. Rusnati M, Oreste P, Zoppetti G, Presta M. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des 2005;11:2489-99. (Pubitemid 40872693)